Sign In
Buy CHRO
$1.35
+0 (+0%)
At Close: Sep 30, 2025
FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), an emerging leader in the development of non-opioid pai
Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules
05:00pm, Thursday, 01'st May 2025
FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatmen
Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine
09:00am, Friday, 20'th Dec 2024
FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatme
FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatme
Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates
09:49am, Thursday, 21'st Nov 2024
FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation, (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced th
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain
08:30am, Tuesday, 29'th Oct 2024
FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain t
Chromocell Announces Amendment to Stock Repurchase Plan
08:45am, Thursday, 24'th Oct 2024
FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain t
Chromocell to Participate in Life Sciences Investor Forum September 19th
08:35am, Monday, 16'th Sep 2024
FREEHOLD, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain
Chromocell Announces Stock Repurchase Plan
08:45am, Wednesday, 07'th Aug 2024
FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain t
Chromocell to Participate in the Virtual Investor Lunch Break Series
09:00am, Monday, 15'th Jul 2024
Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET Live webcast with Frank Knuettel II, Chief Executive Officer and Chief F
Paycom Announces Promotions of Randy Peck to COO, Jennifer Kraszewski to CHRO and Matt Paque to CLO
09:15am, Friday, 31'st May 2024
OKLAHOMA CITY--(BUSINESS WIRE)--Paycom Software, Inc. (NYSE: PAYC) (“Paycom” or the “Company”), a leading provider of comprehensive, cloud-based human capital management software, announced th
PROLOGIS' NEKRITZ AND MCKEOWN TO RETIRE; NEW CLO AND CHRO ANNOUNCED
09:00am, Wednesday, 22'nd May 2024
Briones and Carey to join company's executive committee on Jan. 1, 2025 SAN FRANCISCO , May 22, 2024 /PRNewswire/ -- Prologis (NYSE: PLD) today announced Ed Nekritz and Colleen McKeown will retire as
Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024
09:00am, Monday, 13'th May 2024
FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain tr
Chromocell Issues Letter to Stockholders from Chief Executive Officer
08:30am, Tuesday, 09'th Apr 2024
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
08:30am, Thursday, 21'st Mar 2024
FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatm
